Skip to content
Menu

Oncolytics Biotech Inc. ONCY

Full chart Compare
Set alert

Price alert · ONCY

All alert types
0.35 USD -0.04 (-10.37%)

Regular-session close

0.37 +0.02 +5.66%

After hours · Nov 20, 7:07 PM ET

0.34 Day range 0.3885
0.33 52-week range 1.30
YTD
-59.76%
1 year
-64.64%

5D +0.0206 (+5.57%)

0.35000.40000.4500FriMonTueWedThu0.3906
Market cap
47.66M
EPS (ttm)
-0.30
Shares out
77.07M
Forward P/E
-3.02
YTD return
-59.76%
1-year return
-64.64%
50-day average
1.04
200-day average
1.04
Volume
1.11M
Avg volume
1.16M
Open
0.38
Previous close
0.3906
Day's range
0.34 – 0.3885
52-week range
0.33 – 1.30
Beta
1.51
Price target
4.85 (+1285.9%)

Key statistics

Enterprise value
55.56M
Price / book
2.45
Free cash flow
-15.77M
Total cash
24.85M
Total debt
1.12M
Return on equity
-138.22%
Short % of float
3.89%

Fundamental scorecard

1 of 25 checks passed on ONCY’s reported financials

ValueGrowthProfitabilityHealthDividend

1of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 1 of 5
  • Dividend No data

Statements to Sep 30, 2026.

Financials — quick view

All financials
ONCY Revenue — quarterly 0
ONCY Net income — quarterly -9.71M
ONCY EPS — quarterly -0.08

Earnings

ONCY recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2024Sep 1, 2024-0.08-0.09-0.01-12.50%
Aug 1, 2024Jun 1, 2024-0.08-0.07+0.01+12.50%
May 9, 2024Mar 1, 2024-0.09-0.07+0.02+22.22%
Mar 7, 2024Dec 1, 2023-0.11-0.04+0.07+63.64%
Nov 3, 2023Sep 1, 2023-0.07-0.10-0.03-42.86%
Aug 14, 2023Jun 1, 2023-0.09-0.090.000.00%

Upgrades / downgrades

ONCY analyst upgrades and downgrades
DateFirmActionFromTo
Nov 14, 2024HC Wainwright & Co.reitBuyBuy
Sep 19, 2024HC Wainwright & Co.reitBuyBuy
Aug 21, 2024HC Wainwright & Co.reitBuyBuy
May 14, 2024HC Wainwright & Co.reitBuyBuy
Apr 4, 2024Raymond Jamesinit—Outperform
Mar 8, 2024HC Wainwright & Co.mainBuyBuy

About Oncolytics Biotech Inc.

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Sector
Healthcare
Industry
Biotechnology
Country
Canada

News

Your note

Sign in to keep a note on ONCY — it syncs with the Stock Master app.

Institution ownership

ONCY institution ownership
Holder% heldSharesValueReported
International Assets Investment Management, LLC0.26%198,400179.71KJun 29, 2024
Seeds Investor LLC 0.25%189,941172.05KSep 29, 2024
Goldman Sachs Group Inc0.11%84,99876.99KSep 29, 2024
Royal Bank of Canada0.10%74,54667.52KSep 29, 2024
Citadel Advisors Llc0.10%79,24971.78KSep 29, 2024
Commonwealth Equity Services, LLC0.08%61,11455.36KSep 29, 2024

Fund ownership

ONCY fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.05%41,94237.99KOct 30, 2024